Unleashing our full potential
To accelerate vaccine development, a high-throughput screening platform has been developed that enables the testing of more than 200 different expression approaches per week. This screening platform, named VLPExpressTM, has importantly accelerated the development of Medicago's products and has enabled the production of a broad range of VLP-based vaccine candidates and antibodies.
Antigen-Display PlatformsMedicago has demonstrated the power of VLPs as their size, structure and repetitive display of antigenic patterns allow for a broader and improved immune response. Medicago is developing platforms based on enveloped or capsidic VLPs that can incorporate and display antigens to target diverse diseases. This is particularly useful in cases where the target antigen is ineffective without an adjuvant or when the antigenic sequence is a part of a protein that is difficult to produce or formulate.
Advancing our first line of defense against disease
Medicago is committed to development of VLP-based vaccines targeting a range of infectious diseases of bacterial or viral origin. With the company's core products combating prevalent respiratory and enteric viruses, Medicago's discovery platforms ensure its readiness to combat new and emerging pathogens for insect-borne and zoonotic diseases.
Developing new ways to fight back
An area of avid interest for Medicago is antibody-based therapeutics. The company's discovery activities are targeted towards identification of antibodies for effective treatment of prevalent and emerging infectious agents, including bio-resistant bacteria. The platform's ability to generate a range of antibodies enables development of new technologies to fight global challenges, such as treatment of cases of opioid misuse and opioid exposure.
Leveraging our technologies to develop new cancer vaccines
We are looking to maximizing the potential of our technologies with new indications like immunotherapies for cancer vaccines